A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of beta-amyloid load in an AD cohort

    Thumbnail
    Download
    Citations
    Scopus
    Web of Science
    Altmetric
    5
    4
    Author
    Pedrini, S; Gupta, VB; Hone, E; Doecke, J; O'Bryant, S; James, I; Bush, AI; Rowe, CC; Villemagne, VL; Ames, D; ...
    Date
    2017-10-25
    Source Title
    SCIENTIFIC REPORTS
    Publisher
    NATURE PUBLISHING GROUP
    University of Melbourne Author/s
    Ames, David; Bush, Ashley; Villemagne, Victor; Masters, Colin; Rowe, Christopher; Nigro, Julie; Horne, Malcolm; Yates, Paul
    Affiliation
    Florey Department of Neuroscience and Mental Health
    Melbourne Medical School
    Austin Academic Centre
    Medicine (Austin & Northern Health)
    Eastern Hill Academic Centre
    Medicine (St Vincent's)
    Surgery (St Vincent's)
    Medicine (RMH Academic Centre)
    Medicine (RMH)
    Psychiatry
    Melbourne School of Population and Global Health
    Melbourne School of Psychological Sciences
    School of Biomedical Sciences
    Anatomy and Neuroscience
    Biochemistry and Molecular Biology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Pedrini, S; Gupta, VB; Hone, E; Doecke, J; O'Bryant, S; James, I; Bush, AI; Rowe, CC; Villemagne, VL; Ames, D; Masters, CL; Martins, RN, A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of beta-amyloid load in an AD cohort, SCIENTIFIC REPORTS, 2017, 7
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/194899
    DOI
    10.1038/s41598-017-14020-9
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656630
    Abstract
    Alzheimer's Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer's participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ε4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ε4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial.

    Export Reference in RIS Format     

    Collections